| Objective: Acute myocardial infarction(AMI) is the most common diseases of humans'. It's dangerous and the mortality is high. At present, the traditional treatments including drugs,PCI,thrombolysis and surgery can't regenerate the thanatosis myocardial tissue, but only recovery a part of myocardial tissue's reperfusion,improve the symptoms of myocardial ischemia and heart failure. In addition, they are limited by the time and long-term outcome owes ideal. The patients'quality of life is unable to guarantee. In recent years, it's new dawn for AMI with the transplantation bone marrow stromal stem cells(MSCs).MSCs have the potential of self-renew and differentiation. They can differentiate into various types'cells, including myocardial cells. There are many methods of MSCs transplantation for AMI, such as epicardial injection,endocardial injection,coronary artery catheter injection and intravenous injection, etc. These methods have not only the respective advantages, but also the hidden troubles, for instance trauma and safety. It's suggested that intravenously delivering MSCs is the most safe therapy for AMI. But many experts have questions for its effectiveness and safety, which is the biggest obstacle for intravenously delivering MSCs to treat AMI in clinic. The experiment aims to discuss and explain two questions by calculating the area of myocardial infarction:1.MSCs can differentiate into myocardial cells, which can regenerate the myocardial tissue,reduce mortality and improve patients'long-term quality of life.2.It's no statistical significance between intravenous and epicardial injection. It's the same results in using intravenous injection as well as epicardial injection. It's admitted that intravenously delivering MSCs can replace the epicardial injection, even other methods. All above, it's the solid theoretical basis for intravenously delivering MSCs to use in clinic.Methods: Select the healthy New Zealand rabbits of 2 to 4 months, which are randomized into 3 groups: the control group,the experimentalⅠgroup( epicardial injection),the experimentalⅡgroup (intravenous injection).MSCs from the rabbits were isolated,cultured,purified,signed and detected for transplantation. The rabbits are subjected to AMI by left anterior descending artery occlusion, which the successful proof is S-T section of ECG rising for 30 minutes. Two weeks after induction of AMI ,the control group(n=20)underwent second thoracotomy ,and PBS was injected in infarction myocardial tissue. The experimentalⅠgroup (n=20)underwent second thoracotomy ,too, and MSCs were injected into 3 points infarction myocardial tissue. Meanwhile, MSCs were injected into ear margin vein of experimentalⅡgroup(n=20).Examine the heart function with ultrasonic instruments in the terms of health,AMI,MSCs transplantation. Four weeks after MSCs transplantation, examine the heart function, again. Then, take the hearts,calculate the areas,record the results and analysis the statistical results.Results:1.Through the control group compares with the experimentalⅠgroup and the experimentalⅡgroup respectively, the differences have statistical significances(P<0.05).2. Through the experimentalⅠgroup compares with the experimentalⅡgroup, the difference doesn't have statistical significances(P〉0.05).Conclusion:1.MSCs can differentiate into myocardial cells, save thanatosis myocardial tissue by transplanting MSCs into myocardial tissue, not only that ,it can make the area of AMI more and more smaller and new blood vessels increased. All can prove that transplanting MSCs is a effective therapy for AMI.2.From the statistical results, it's the same effect in regeneration of myocardial tissue,new blood vessels number and reducing the area of AMI with two different methods (epicardial injection and intravenous injection). All can prove that maybe intravenously delivering MSCs for AMI replace the epicardial injection. |
PDF Full Text Request